Thomas Steyer’s 4D Molecular Therapeutics FDMT Stock Holding History

Thomas Steyer’s Portfolio FDMT Stock Details FDMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-100,000	Closed	-$4.14M	–	240
2020 Q4	$4.14M	Buy	+100,000	New	+$4.13M	0.02%	127

Other funds holding FDMT

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return

Thomas Steyer's FDMT Position: Q1 2021 in Review

Thomas Steyer sold out of 4D Molecular Therapeutics (FDMT) in Q1 2021, closing a stake of 100,000 shares — an estimated $4.14M sold.

Thomas Steyer first reported a position in FDMT in Q4 2020 and held it in 1 quarter. The position peaked at $4.14M in Q4 2020. 64 funds tracked by Wall St. Rank hold FDMT as of Q1 2021.

Thomas Steyer reported no remaining 4D Molecular Therapeutics position as of Q1 2021 after selling out during the quarter.
Thomas Steyer sold 100,000 4D Molecular Therapeutics shares in Q1 2021, an estimated $4.14M.
Thomas Steyer first reported a position in 4D Molecular Therapeutics in Q4 2020 and held it in 1 quarter.
Thomas Steyer's 4D Molecular Therapeutics position peaked at $4.14M in Q4 2020.
64 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q1 2021.

Based on Farallon Capital Management's 13F filing for Q1 2021, filed 17 May 2021.